For US Healthcare Professionals Only
Congress Materials
FILTER
FILTER
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
A network meta-analysis of cumulative clinical benefit of anti-IL biologics for the treatment of moderate to severe psoriasis over 48–52 weeks
A Systematic Literature Review of Health-Related Quality of Life and Other Patient Reported Outcomes Across Key Subgroups in Hidradenitis Suppurativa
Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Achieving Increasingly Stringent Clinical Disease Control Criteria is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controll
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomize
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Oral Presentation American College of Rheumatology (ACR), 2022
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Assessment of the Performance of the IHS4-55 Using Data from a Phase 2 Study of Bimekizumab in Patients with Hidradenitis Suppurativa
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
Association of DLQI 0/1 with relative PASI improvements in subgroups of patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Poster Fall Clinical PA + NP, 2023
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Pooled results through two years from the BE SURE and BE RADIANT phase 3 trials
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Bimekizumab efficacy over two years in patients with moderate to severe plaque psoriasis with scalp and nail involvement who switched from adalimumab, ustekinumab, or secukinumab: Results from the BE SURE, BE VIVID, BE BRIGHT, and BE RADIANT phase 3/3b tr
Bimekizumab efficacy through 96 weeks in patients with moderate to severe plaque psoriasis: Patient-reported outcomes from the BE RADIANT phase 3b trial
Poster Winter Clinical, 2023
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Poster Winter Clinical Miami, 2023
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Bimekizumab improved efficacy measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Bimekizumab Improves Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study
Oral Presentation American College of Rheumatology (ACR), 2022
Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy and Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study
Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo-controlled, active reference study
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Bimekizumab in patients with active non-radiographic axial spondyloarthritis and active ankylosing spondylitis: 24-week efficacy and safety from the BE MOBILE phase 3 studies
Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab
Poster RheumNow Live! (RNL), 2023
Bimekizumab in patients with psoriatic arthritis: 3-year results for overall and tumor necrosis factor inhibitor (TNFi)-naïve populations from a phase 2b open-label extension study
Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study
Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Poster Fall Clinical PA + NP, 2023
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open- label extension trial
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Poster Winter Clinical, 2023
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Poster Winter Clinical Miami, 2023
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Bimekizumab safety and tolerability in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in five phase 3/3b clinical trials
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Poster Winter Clinical Miami, 2023
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Poster Winter Clinical, 2023
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Poster Winter Clinical Miami, 2023
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Oral Presentation American College of Rheumatology (ACR), 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Oral Presentation American College of Rheumatology (ACR), 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial
Bimekizumab versus secukinumab in plaque psoriasis: Cumulative clinical and health‑related quality of life benefit through 2 years of the BE RADIANT phase 3b trial and open‑label extension
Both IL-17RA and IL-17RC receptor complexes are required for IL-17A- and IL-17F-driven inflammation
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Efficacy and safety of bimekizumab in bDMARD-naïve patients with psoriatic arthritis: 24-week results from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study
Efficacy and safety of bimekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: 16-week results from BE COMPLETE, a phase 3, randomised, double-blind placebo-controlled study
Poster Skin of Color (SOC), 2022
Efficacy of bimekizumab in patients with psoriasis and skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials
Medical Symposium Winter Clinical, 2023
Family Matters: The central role of the IL-17 family of cytokines in inflammatory diseases
Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis
Impact of the CIMplicity® Patient Support Program on Persistence to Certolizumab Pegol Treatment: A Retrospective Cohort Analysis of Claims Data in the United States
Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Neutrophils and the IL-17 Axis Play a Key Pathological Role in Hidradenitis Suppurativa
Poster Skin of Color (SOC), 2022
Patient-reported quality of life in patients with psoriasis with skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials
Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Single-cell sequencing of freshly isolated cells from lesional and peri-lesional skin to explore cellular origins of IL-17 isoforms in psoriasis
Stable plasma concentration of certolizumab pegol is associated with clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year
Treatment Journey of Patients with Non-Radiographic Axial Spondyloarthritis in a US Rheumatology Office Setting: A Retrospective Chart Review
Medical Symposium Congress of Clinical Rheumatology (CCR) East, 2023
Understanding the Pathobiology of Axial Spondyloarthritis and Psoriatic Arthritis
Validation of the HS-IGA: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials